Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

NCT06134362 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

3508

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: CAB LA

Sponsor

ViiV Healthcare

Collaborators

[object Object]
[object Object]